Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Cytomegalovirus Infection

  Free Subscription


Articles published in Bone Marrow Transplant

Retrieve available abstracts of 18 articles:
HTML format
Text format



Single Articles


    June 2018
  1. SOLANO C, Gimenez E, Albert E, Mateo EM, et al
    Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.
    Bone Marrow Transplant. 2018 Jun 13. pii: 10.1038/s41409-018-0251.
    PubMed     Text format     Abstract available


    May 2018
  2. METAFUNI E, Chiusolo P, Sica S, Laurenti L, et al
    Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants.
    Bone Marrow Transplant. 2018 May 24. pii: 10.1038/s41409-018-0200.
    PubMed     Text format     Abstract available


  3. LINDEMANN M, Eiz-Vesper B, Steckel NK, Tischer S, et al
    Adoptive transfer of cellular immunity against cytomegalovirus by virus-specific lymphocytes from a third-party family donor.
    Bone Marrow Transplant. 2018 May 8. pii: 10.1038/s41409-018-0209.
    PubMed     Text format    


    April 2018
  4. SOLANO C, Talaya A, Gimenez E, Albert E, et al
    Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?
    Bone Marrow Transplant. 2018 Apr 26. pii: 10.1038/s41409-018-0191.
    PubMed     Text format    


  5. PERIC Z, Wilson J, Durakovic N, Ostojic A, et al
    Early human cytomegalovirus reactivation is associated with lower incidence of relapse of myeloproliferative disorders after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2018 Apr 16. pii: 10.1038/s41409-018-0172.
    PubMed     Text format     Abstract available


  6. ALSULIMAN T, Kitel C, Dulery R, Guillaume T, et al
    Cytotect(R)CP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study.
    Bone Marrow Transplant. 2018 Apr 13. pii: 10.1038/s41409-018-0166.
    PubMed     Text format     Abstract available


    January 2018
  7. CESARO S, Crocchiolo R, Tridello G, Knelange N, et al
    Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0016.
    PubMed     Text format     Abstract available


    October 2017
  8. ALBERT E, Solano C, Gimenez E, Focosi D, et al
    The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.
    Bone Marrow Transplant. 2017 Oct 30. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


    June 2017
  9. SOLANO C, Gimenez E, Pinana JL, Hernandez-Boluda JC, et al
    When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    February 2017
  10. IGLESIAS L, Perera MM, Torres-Minana L, Pena-Lopez MJ, et al
    CMV viral load in bronchoalveolar lavage for diagnosis of pneumonia in allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2017 Feb 20. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


    January 2017
  11. SHAW BE, Mayor NP, Szydlo RM, Bultitude WP, et al
    Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants.
    Bone Marrow Transplant. 2017 Jan 16. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    October 2016
  12. BAO X, Zhu Q, Xue S, Xu Y, et al
    Risk factors of clinically refractory CMV reactivation following allogeneic HSCT: a single-center study in China.
    Bone Marrow Transplant. 2016 Oct 17. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    April 2016
  13. RAMANATHAN M, Teira P, Battiwalla M, Barrett J, et al
    Impact of early CMV reactivation in cord blood stem cell recipients in the current era.
    Bone Marrow Transplant. 2016 Apr 4. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    March 2016
  14. CROCCHIOLO R, Castagna L, Furst S, Devillier R, et al
    The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.
    Bone Marrow Transplant. 2016 Mar 21. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    December 2015
  15. SOLANO C, Gimenez E, Pinana JL, Vinuesa V, et al
    Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood.
    Bone Marrow Transplant. 2015 Dec 7. doi: 10.1038/bmt.2015.
    PubMed     Text format    


    June 2015
  16. NOVIELLO M, Forcina A, Veronica V, Crocchiolo R, et al
    Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall.
    Bone Marrow Transplant. 2015 Jun 15. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  17. VON BAHR L, Blennow O, Alm J, Bjorklund A, et al
    Increased incidence of chronic GvHD and CMV disease in patients with vitamin D deficiency before allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2015 Jun 1. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  18. HAMILTON BK, Rybicki L, Sekeres M, Kalaycio M, et al
    Racial differences in allogeneic hematopoietic cell transplantation outcomes among African Americans and whites.
    Bone Marrow Transplant. 2015;50:834-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cytomegalovirus Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: